|
|
119 Fourth Avenue
Needham, MA 02494 USA
phone:(781) 433-0771
fax:(781) 433-0262
|
|
| Symbol |
CLDX |
| Exchange |
NASDAQ |
| Founded |
1975 |
| Employees |
|
|
|
| www.celldextherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Pre-clinical and clinical development programs |
|
| Management |
| Anthony S. Marucci, Founder, President and Chief Executive Officer; Avery W. ("Chip") Catlin, Senior Vice President and Chief Financial Officer; Tibor Keler, Ph.D., Founder, Senior Vice President and Chief Scientific Officer; Thomas Davis, M.D., Senior Vice President and Chief Medical Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| biotechnology, antigen presenting cell targeting technology, monoclonal antibodies, dendritic cells, synergistic |
|
|
|
| Description |
|
Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Their core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious and inflammatory diseases through their novel �targeted immunization� approach. They have developed an Antigen Presenting Cell Targeting Technology (APC Targeting Technology) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells or APCs - particularly dendritic cells. They are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers as well as within their growing activities in infectious and inflammatory diseases. |
|
| Technology / Differentiation |
| Celldex's proprietary technology platform uses fully human monoclonal antibodies administered directly to patients to target dendritic cells and macrophages key cells within the immune system. To generate an effective immune response, a vaccine needs to be taken up and processed by these cells, which are also known as Antigen Presenting Cells or APCs. Our recombinant antibody vaccines are designed as off-the-shelf products that enhance the efficiency and effectiveness of vaccination by targeting the vaccine to APCs in the body. Our product candidates using the APC technology include CDX-1307, which is currently in two Phase I clinical trials for multiple cancers. Additional new product candidates are planned to enter clinical development for oncology and infectious disease. |
|
|
| Competitors / Substitutes / Alternatives |
CancerVax Corporation (CNVX), Corixa Corporation (CRXA), Dendreon Corporation (DNDN)
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
